Patents Issued in April 30, 2019
-
Patent number: 10272014Abstract: Systems and methods for providing network connectivity and remote monitoring, optimization, and control of pool/spa equipment are provided. “Internet-of-Things” (IoT) functionality is provided for pool and spa equipment in a flexible and cost-effective manner. Network connectivity and remote monitoring/control of pool and spa equipment is provided by various components such as a network communication and local control subsystem installed in pool/spa equipment, and other components. Also disclosed are various control processes (“pool logic”) which can be embodied as software code installed in any of the various embodiments of the present disclosure.Type: GrantFiled: January 23, 2017Date of Patent: April 30, 2019Assignee: Hayward Industries, Inc.Inventors: Kevin Potucek, James Murdock, James Carter, Gregory Fournier, Arthur W. Johnson, III, David Blaine, Jason DeBruin, Bruce Aubrey, Scott Petty, Jason Parcell, Craig Horrocks
-
Patent number: 10272015Abstract: Methods to enable a visual check on the mixing proper pharmaceutical compounding kits. The methods include providing a kit with a colored inactive to be added to the mixture. When the mixture is uniform or resembles a predetermined color, the mixture is assumed to be properly mixed.Type: GrantFiled: October 24, 2017Date of Patent: April 30, 2019Inventors: Austin Bonderer, Clark Levi
-
Patent number: 10272016Abstract: A catheter with an imaging assembly is disclosed. The catheter is used with a console for viewing and/or storing images obtained from the catheter. The catheter may be a feeding tube assembly. The imaging assembly on the feeding tube assembly allows a user to confirm placement of the feeding tube assembly in the patient's alimentary canal.Type: GrantFiled: April 21, 2016Date of Patent: April 30, 2019Assignee: KPR U.S., LLCInventors: Robert Allyn, Robert B. Gaines, Thomas G. Lewis, Michael C. Dorsey, William J. Byrd, Michael D. Hudspeth, Glen Branconier
-
Patent number: 10272017Abstract: An aqueous dental glass ionomer composition comprising (A) a reactive particulate glass, (B) a water-soluble polymer comprising acidic groups, which is reactive with the particulate glass in a cement reaction, (C) a water-soluble, hydrolysis-stable monomer having a single polymerizable double bond and optionally a carboxylic acid group or hydroxyl group; (D) a water-soluble, hydrolysis-stable polymerizable crosslinker having at least two polymerizable carbon-carbon double bonds; and (E) a polymerization initiator system.Type: GrantFiled: April 13, 2017Date of Patent: April 30, 2019Assignee: DENTSPLY SIRONA Inc.Inventors: Caroline Renn, Oliver Elsner, Florian Szillat, Joachim Klee, Christoph Weber, Uwe Walz, Christian Scheufler, Andrew Lichkus, Xiaoming Jin
-
Patent number: 10272018Abstract: A beauty care product is provided. The beauty care product has a multi-layered barrier patch with a non-foamed first layer and a foamed second layer. The non-foamed first layer has a non-foamed polymer film with a first surface and a thickness from 5 microns to 250 microns. The foamed second layer has a foamed polymer film comprising a Mean Void Volume Percentage from 45% to 80% and a thickness of from 10 microns to 250 microns. The beauty care product also has a cosmetic composition with an effective amount of a skin active agent and a pressure sensitive adhesive.Type: GrantFiled: October 18, 2016Date of Patent: April 30, 2019Assignee: The Procter & Gamble CompanyInventors: Emily Charlotte Boswell, Elizabeth Anne Wilder, Michael Remus
-
Patent number: 10272019Abstract: Core-shell particles have a hydrophobic core and a shell formed of or containing hyperbranched polyglycerol (HPG). The HPG can be covalently bound to the one or more materials that form the core or coated thereon. The HPG coating can be modified to adjust the properties of the particles. For example, unmodified HPG coatings impart stealth properties to the particles which resist non-specific protein absorption. Alternatively, the hydroxyl groups on the HPG coating can be chemically modified to form functional groups that react with functional groups on tissue or otherwise interact with tissue to adhere the particles to the tissue, cells, or extracellular materials, such as proteins. Such functional groups include, but not limited to, aldehydes, amines, and O-substituted oximes. Topical formulation for application to the skin contain these HPG coated nanoparticles.Type: GrantFiled: May 11, 2015Date of Patent: April 30, 2019Assignee: Yale UniversityInventors: Yang Deng, Asiri Ediriwickrema, William M. Saltzman
-
Patent number: 10272020Abstract: A cleaning composition comprising a base and an inorganic particulate material selected from the group consisting of spherical perlite, alumina, vermiculite, nepheline and mixtures thereof, wherein the spherical perlite comprises microspheres that are substantially closed and hollow.Type: GrantFiled: June 23, 2016Date of Patent: April 30, 2019Assignee: Imertech SASInventors: Sam Jolliff, Anabelle Huguette Renee Legrix, Thierry Casteran
-
Patent number: 10272021Abstract: A subject matter of the present invention is a composition comprising: a) at least multilayer spherical composite particles comprising i) a core comprising at least one material A having a refractive index ranging from 1.3 to 1.8; and ii) at least one layer covering said core, comprising at least one material B having a refractive index ranging from 1.9 to 3.1; and iii) optionally at least one second layer covering the material B, comprising at least one material C having a refractive index ranging from 1.3 to 1.8; said composite particles being present in an amount less than 28.0% by weight relative to the total weight of the composition; and b) at least one UV-screening agent. This composition is for topical use and is more particularly intended for the photoprotection of the skin and/or hair against ultraviolet (UV) radiation.Type: GrantFiled: September 16, 2015Date of Patent: April 30, 2019Assignee: L'OREALInventors: Yasuko Nagamatsu, Didier Candau, Angelina Roudot, Yannick Jolly
-
Patent number: 10272022Abstract: The present invention relates generally to oral care compositions, and more specifically to oral care compositions suitable for cleaning the oral cavity. Methods of use are also disclosed.Type: GrantFiled: March 27, 2017Date of Patent: April 30, 2019Assignee: Johnson & Johnson Consumer Inc.Inventors: Lauren Carratello, Dexter M. Williams, Saroja Narasimhan, E. Eric Engelman, Joseph J. LiBrizzi
-
Patent number: 10272023Abstract: Compositions are provided and described herein which include cosmetic and hair conditioning compositions having a mixture of stearamidopropyl dimethylamine and behenamidopropyl dimethylamine. Also provided are methods for conditioning hair using such mixtures.Type: GrantFiled: May 19, 2017Date of Patent: April 30, 2019Assignee: INOLEX Investment CorporationInventors: Rocco Burgo, Jeffrey Parker
-
Patent number: 10272024Abstract: The present disclosure provides improved methods for administration or application of cosmetic or medical agents, including, but not limited to, dermal fillers and Botox-type injectable agents.Type: GrantFiled: November 28, 2016Date of Patent: April 30, 2019Inventor: Muhammad Mirza
-
Patent number: 10272025Abstract: The present invention relates to a perfuming eau de toilette or eau de parfum composition comprising a high proportion of alcohol, for direct application on the skin or hair by spraying. More specifically, it relates to a sprayable perfume composition having excellent properties such as persistence of the olfactory note once applied on the skin. The composition is transparent and contains ethanol, 0 to 30% by weight of water, 3 to 40% by weight of a perfume concentrate and a copolymer of vinylpyrrolidone and vinyl acetate.Type: GrantFiled: June 29, 2015Date of Patent: April 30, 2019Assignee: LVMH RECHERCHEInventors: Karine Chevet, Valerie Alard, Marie-Laure Souvie, Brigitte Noe
-
Patent number: 10272026Abstract: Provided are water-in-oil emulsion compositions which comprise: a. an alkalizing agent; b. a dimethicone surfactant; c. a fatty alcohol having a C16-36 alkyl group; d. an amphoteric surfactant; e. a waxy ether or a waxy ester; and f. a thickener. Such compositions may further comprise a hair colorant compound comprising an oxidation dye, and are suitable as a hair color-altering composition. Also provided are kits and methods of using said compositions.Type: GrantFiled: July 31, 2017Date of Patent: April 30, 2019Assignee: L'OREALInventor: Jeffrey Wang
-
Patent number: 10272027Abstract: Provided are cosmetic compositions comprising a silicone acrylate copolymer, a polypropylsilsesquioxane film forming resin, a hydrocarbon-based resin, a non-volatile oil, a volatile hydrocarbon solvent, and optionally a wax, wherein the ratio of the silicone acrylate copolymer to the polypropylsilsesquioxane resin is from about 1:1 to about 4:1, the weight percent ratio of silicone acrylate copolymer plus the polypropylsilsesquioxane film forming resin to the at least one hydrocarbon-based resin is from about 1.5:1 to about 30:1 on a dry weight basis, and the total amount of the polypropyl silsesquioxane film forming resin and the silicone acrylate copolymer is greater than about 10% on a dry weight basis relative to the weight of the composition.Type: GrantFiled: June 18, 2014Date of Patent: April 30, 2019Assignee: L'OREALInventors: Hy Si Bui, Rita Jaky El-Khouri, Mita Trivedi
-
Patent number: 10272028Abstract: A method of reducing melanogenesis in skin is disclosed. The method can include topically applying to skin in need thereof a composition comprising an effective amount of an aqueous and glycerin extract of Rhododendron ferrugineum (alpine rose) leaf to reduce melanocyte pigmentation in the skin.Type: GrantFiled: October 31, 2017Date of Patent: April 30, 2019Assignee: Mary Kay Inc.Inventor: David Gan
-
Patent number: 10272029Abstract: The present invention provides methods and compositions useful in the regeneration of damaged, lost and/or degenerated tissue in humans and animals. In certain embodiments, the present invention provides an acellular bioabsorbable tissue regeneration matrix, methods of making such a matrix, and methods of using such a matrix for the regeneration of damaged, lost and/or degenerated tissue. In certain embodiments, methods and compositions of the present invention are useful in the treatment of damaged, lost and/or degenerated nerve tissue.Type: GrantFiled: March 11, 2016Date of Patent: April 30, 2019Assignee: GENESIS TECHNOLOGIES LIMITEDInventor: Jan-Eric Ahlfors
-
Patent number: 10272030Abstract: Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, X and m are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: July 10, 2017Date of Patent: April 30, 2019Assignee: Cytokinetics, Inc.Inventors: Zhe Yang, Alex R. Muci, Jeffrey Warrington, Gustave Bergnes, Bradley P. Morgan, Chihyuan Chuang, Antonio Romero, Scott Collibee, Xiangping Qian, Pu-Ping Lu
-
Patent number: 10272031Abstract: The composition containing a pamoate salt of donepezil, the method of preparation and the use thereof are disclosed.Type: GrantFiled: October 25, 2017Date of Patent: April 30, 2019Inventor: Zi-Qiang Gu
-
Patent number: 10272032Abstract: This disclosure provides pharmaceutical adenovirus formulations, in particular, liquid pharmaceutical formulations comprising adenoviruses.Type: GrantFiled: April 24, 2018Date of Patent: April 30, 2019Assignee: Janssen Vaccines & Prevention B.V.Inventor: Janik Adriaansen
-
Patent number: 10272033Abstract: Biopharmaceuticals, such as vaccine agents and probiotics, are encapsulated in carbohydrate-glass particles and embedded in an amorphous polymer substrate to produce polymeric compositions containing ambient-temperature stable biopharmaceuticals for syringeless administration to patients such as via dissolvable films, micro-needle patches and similar medical delivery devices. The amorphous polymer substrate is soluble in both water and volatile organic solvents, yet the carbohydrate-glass particles are insoluble in organic solvents. A method for formulation of the polymeric compositions containing ambient-temperature stable biopharmaceuticals includes combining biopharmaceuticals encapsulated in carbohydrate-glass particles with polymer in organic solvent and evaporating the organic solvent to yield a water soluble polymeric composition containing ambient-temperature stable biopharmaceuticals.Type: GrantFiled: May 30, 2014Date of Patent: April 30, 2019Assignee: UNIVERSAL STABILIZATION TECHNOLOGIES, INCInventor: Victor Bronshtein
-
Patent number: 10272034Abstract: Disclosed herein are compositions and methods for the treatment of otic disorders with immunomodulating agents and auris pressure modulators. In these methods, the auris compositions and formulations are administered locally to an individual afflicted with an otic disorder, through direct application of the immunomodulating and/or auris pressure modulating compositions and formulations onto the auris media and/or auris interna target areas, or via perfusion into the auris media and/or auris interna structures.Type: GrantFiled: June 19, 2015Date of Patent: April 30, 2019Assignees: OTONOMY, INC., THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Jay Lichter, Andrew M. Trammel, Fabrice Piu, Qiang Ye, Luis A. Dellamary, Carl Lebel, Jeffrey P. Harris, Benedikt Vollrath, Sergio G. Duron, Michael Christopher Scaife
-
Patent number: 10272035Abstract: A method to provide a therapeutic agent to an eye of a patient by implanting or inject a device that stably fits a particular location or position in the eye. The method thus provides agent inside the eye for a longer duration of agent release over a space-occupying area inside the eye.Type: GrantFiled: September 19, 2016Date of Patent: April 30, 2019Inventor: Gholam A. Peyman
-
Patent number: 10272036Abstract: A process for selective transvinylation of a reactant carboxylic acid with a reactant vinyl ester to give a product vinyl ester and the corresponding acid of the reactant vinyl ester in the presence of one or more ruthenium catalysts, wherein a) the reactant vinyl ester, the reactant carboxylic acid and the ruthenium catalyst are supplied to a reactor, wherein b) the molar ratio of reactant vinyl ester to reactant carboxylic acid is 1:3 to 3:1, and c) the transvinylation reaction is conducted, d) on completion of the transvinylation reaction, the reactant vinyl ester and the corresponding acid are separated from the reaction mixture by distillation, e) the product vinyl ester is separated by distillation from the bottom product of the distillation, and f) the remaining reaction mixture is recycled into the reactor.Type: GrantFiled: November 20, 2014Date of Patent: April 30, 2019Assignee: Intervet Inc.Inventors: Moti Harel, Swetha Kambalapally
-
Patent number: 10272037Abstract: Provided herein are methods for preventing or alleviating the symptoms of and inflammation associated with inflammatory diseases and conditions of the gastrointestinal tract, for example, those involving the esophagus. Also provided herein are pharmaceutical compositions useful for the methods of the present invention.Type: GrantFiled: September 18, 2017Date of Patent: April 30, 2019Assignees: The Regents of the University of California, Meritage Pharma, Inc.Inventors: Ranjan Dohil, John Bastian, Seema Aceves, Elaine Phillips, Malcolm Hill
-
Patent number: 10272038Abstract: An orally administered dosage form that facilitates delivery of an agent locally in the buccal cavity for a sustained period of time includes mucoadhesive particles that are made of at least a mucoadhesive material combined with the agent, and which are dispersed in a disintegrating film. The dosage form is capable of delivering an agent to a patient at the desired oral mucosa site over an extended period of time while reducing patient discomfort or annoyance associated with conventional sustained release mucoadhesive films that must reside on the oral mucosa during the period of sustained release.Type: GrantFiled: May 8, 2017Date of Patent: April 30, 2019Assignee: Intelgenx Corp.Inventors: Rodolphe Obeid, Nadine Paiement
-
Patent number: 10272039Abstract: A sodium nitrite formulation for topical administration is described. The formulation includes an aqueous solution of non-acidified sodium nitrite dispersed in a white petrolatum ointment. The concentration of sodium nitrite in the formulation is about 0.5% to about 3.0% by weight. To prepare the formulation, non-acidified sodium nitrite is completely dissolved in a small quantity of water, sterile filtered and dispersed in white petrolatum ointment.Type: GrantFiled: November 10, 2015Date of Patent: April 30, 2019Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Haksong Jin, George Grimes, Deborah Sperling, Gopal Potti, Caterina P. Minniti, Gregory J. Kato
-
Patent number: 10272040Abstract: The present invention is directed to a liposomal formulation for ocular drug delivery comprising (i) liposomes comprising at least one lipid bilayer, and (ii) a prostaglandin drug and/or a prostaglandin derivative associated in the liposomes, wherein the liposomes have a mean diameter of less than 2???. The present invention is also directed to a pharmaceutical comprising the liposomal formulation and a method of producing the liposomal formulation for ocular drug delivery. Additionally, the present invention is directed to a method of treating or preventing an ocular disease, comprising administering the liposomal formulation or the pharmaceutical composition to a subject in need thereof.Type: GrantFiled: August 12, 2011Date of Patent: April 30, 2019Assignees: Nanyang Technological University, Singapore Health Services Pte LtdInventors: Subramanian Venkatraman, Jayaganesh V. Natarajan, Tina Wong, Yin Chiang Freddy Boey
-
Patent number: 10272041Abstract: The present invention relates to a liposomal formulation for oral delivery of a bioactive agent that considers pH stability and oxidative stability of a bioactive ingredient. These lipid formulations are superior to conventional liposomes due to their stability, thereby circumventing the need for intra-venous delivery of bioactive agents. In one embodiment, the methods and compositions of the present invention relate to the oral delivery of insulin or a prodrug thereof.Type: GrantFiled: March 14, 2014Date of Patent: April 30, 2019Assignee: THE PENN STATE RESEARCH FOUNDATIONInventors: Mark Kester, Karam El-Bayoumy, Christine Skibinski, Arunangshu Das
-
Patent number: 10272042Abstract: The invention compositions comprising a continuous hydrophobic phase and liposomes as a vehicle for delivery of an antigen capable of inducing a cytotoxic T lymphocyte (CTL) response and methods for their use in the treatment of cancer.Type: GrantFiled: February 14, 2018Date of Patent: April 30, 2019Assignee: IMMUNOVACCINE TECHNOLOGIES INC.Inventors: Pirouz M. Daftarian, Marc Mansour, Bill Pohajdak, Robert G. Brown, Wijbe M. Kast
-
Patent number: 10272043Abstract: The present invention comprises methods and compositions for the reduction of oxalate in humans. For example, the invention provides methods and compositions for the delivery of one or more oxalate-reducing enzymes embedded in particle compositions. The compositions of the present invention are suitable in methods of treatment or prevention of oxalate-related conditions including, but not limited to, hyperoxaluria, absorptive hyperoxaluria, enteric hyperoxaluria, primary hyperoxaluria, idiopathic calcium oxalate kidney stone disease (urolithiasis), vulvodynia, oxalosis associated with end-stage renal disease, cardiac conductance disorders, inflammatory bowel disease, Crohn's disease, ulcerative colitis, and patients who have undergone gastrointestinal surgery and bariatric surgery (surgery for obesity), and/or who have undergone antibiotic treatment.Type: GrantFiled: October 27, 2014Date of Patent: April 30, 2019Assignee: OXTHERA INTELLECTUAL PROPERTY ABInventors: Qingshan Li, Harmeet Sidhu
-
Patent number: 10272044Abstract: The apparatus and methods of the present invention are of use for the production of emulsion-based microparticles containing a biological or chemical agent. In particular, the apparatus provides a vessel; packing material situated inside such vessel and may further provide material capable of insertion into both ends of said vessel for enclosure of the packing material. In a particular embodiment, the apparatus is a packed bed apparatus. The methods include production of emulsion based microparticles containing a biological or chemical agent. The usefulness of the present invention is that the apparatus and methods of the present invention provide for a low-shear, non-turbulent, production of emulsion-based microparticles that provides a narrow, reproducible, particle size distribution, capable of use with both large and small volumes that is capable of being conveniently scaled up while providing predictable emulsion properties.Type: GrantFiled: November 14, 2014Date of Patent: April 30, 2019Assignee: Evonik CorporationInventor: Ehud Zeigerson
-
Patent number: 10272045Abstract: The present invention relates to treating malignancies such as tumors or cancers by orally administering lyophilized compositions comprising arsenic to a subject in such need. Malignancies include various hematological malignancies, such as acute myeloid leukemia (AML) including acute promyelocytic leukemia (APL), myelodysplastic syndrome (MDS), multiple myeloma (MM) and lymphomas and solid tumors including glioblastoma multiforme and breast cancer. Arsenic treatment has shown great promise in the treatment of several cancers but requires daily intravenous (IV) administration. This invention relates to a novel formulation comprising a lyophilized compositions comprising arsenic. As a result, the formulation facilitates a systemic bioavailability comparable to that of intravenous (IV) administration of arsenic trioxide currently practiced.Type: GrantFiled: October 1, 2018Date of Patent: April 30, 2019Assignee: Orsenix Holdings BVInventors: Krishna Vaddi, Kumar Kurumaddali
-
Patent number: 10272046Abstract: The present invention relates to pharmaceutical compositions containing a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide including formulations of the solid dispersions into powders, granules and mini-tablets, methods for manufacturing and processing the powders, granules and mini-tablets, and methods for treating cystic fibrosis employing the pharmaceutical composition.Type: GrantFiled: June 13, 2016Date of Patent: April 30, 2019Assignee: Vertex Pharmaceuticals IncorporatedInventors: Eleni Dokou, Shahla Jamzad, John P. Caesar, Jr., Majed Fawaz, Laura Das, Chong-Hui Gu, Patricia Nell Hurter, Meghna Jai Israni, Meghan M. Johnston, Dragutin Knezic, Andrew G. Kuzmission, HongRen Wang
-
Patent number: 10272047Abstract: The present invention provides pharmaceutical formulations for oral administration of antisense oligonucleotides, such as antisense oligonucleotides against SMAD7. The pharmaceutical formulations can be used to treat Crohn's disease, ulcerative colitis and chronic inflammatory bowel disease.Type: GrantFiled: October 26, 2016Date of Patent: April 30, 2019Assignee: Nogra Pharma LimitedInventors: Sergio Baroni, Salvatore Bellinvia, Francesca Viti
-
Patent number: 10272048Abstract: In a delayed release formulation comprising a core containing a drug and a delayed release coating for providing intestinal release, release of the drug in the colon is accelerated by including an isolation layer between the core and the delayed release coating. The delayed release coating comprises an inner layer and an outer layer. The outer layer comprises a pH dependently soluble polymeric material which has a pH threshold at about pH 5 or above. The inner layer comprises a soluble polymeric material which is soluble in intestinal fluid or gastrointestinal fluid, said soluble polymeric material being selected from the group consisting of a polycarboxylic acid polymer that is at least partially neutralized, and a non-ionic polymer, provided that, where said soluble polymeric material is a non-ionic polymer, said inner layer comprises at least one additive selected from a buffer agent and a base.Type: GrantFiled: September 16, 2016Date of Patent: April 30, 2019Assignee: Tillotts Pharma AGInventors: Felipe Josè Oliveira Varum, Roberto Carlos Bravo González, Thomas Buser, Abdul Waseh Basit, Ana Cristina Freire
-
Patent number: 10272049Abstract: Provided are a gene carrier using cell-derived nanovesicles and a method for preparing the same. The gene carrier prepared by inserting a gene into the nanovesicles artificially outbudded from a plasma membrane has excellent delivery efficiency to a target organ and cells, induces long-term regulation of gene expression, and facilitates mass production due to a simple preparation process, and thus can be used as a core technique for the gene or cell therapeutic agent field.Type: GrantFiled: April 24, 2017Date of Patent: April 30, 2019Assignee: University-Industry Foundation, Yonsei UniversityInventors: Seung-Woo Cho, Yoon Hee Jin
-
Patent number: 10272050Abstract: This disclosure relates to nanoparticles, compositions, methods of making, and methods of use thereof.Type: GrantFiled: October 14, 2015Date of Patent: April 30, 2019Assignees: The Brigham and Women's Hospital, Inc., President and Fellows of Harvard CollegeInventors: Omid C. Farokhzad, Won Il Choi, Ulrich von Andrian, Nazila Kamaly
-
Patent number: 10272051Abstract: A method to treat the skin condition atopic dermatitis is described in this invention. The method comprises topical application of a composition containing cannabinoids, specifically cannabidiol and cannabigerol at a concentration of 3%-20% by weight of the composition. The method may further comprise administering chewing gum containing cannabinoids such as cannabidiol. Cannabidiol and cannabigerol may be sourced naturally or synthetically.Type: GrantFiled: August 21, 2018Date of Patent: April 30, 2019Assignee: Axim Biotechnologies, Inc.Inventors: Lekhram Changoer, George Anastassov
-
Patent number: 10272052Abstract: Disclosed herein are compositions and methods for treating tauopathies such as Alzheimer's disease (AD). Also provided herein are methods of reducing or disrupting tau aggregation in a subject, and methods of reducing tau protein in a subject. The methods may include administering to the subject a therapeutic amount of hexachlorophene, or a pharmaceutically acceptable salt thereof. Further provided herein are pharmaceutical compositions comprising hexachlorophene, or a pharmaceutically acceptable salt thereof, for the treatment of a tauopathy in a subject.Type: GrantFiled: February 26, 2018Date of Patent: April 30, 2019Assignee: University of South FloridaInventors: Umesh Kumar Jinwal, Vetriselvan Manavalan
-
Patent number: 10272053Abstract: A method of delivering a compound of interest to the lungs of a subject by the intravenous injection of Sertoli cells loaded with a plurality of chitosan nanoparticles coupled with the compound of interest is provided. Testis-derived rat Sertoli cells were pre-loaded with chitosan nanoparticles coupled with or without the drug curcumin, pre-labeled with a fluorescent cell marker and then injected intravenously into the control or asthmatic mouse model host. Intact pre-loaded, pre-labeled Sertoli cells were present in the lungs at 15 minutes post-injection, appeared entrapped in the pulmonary pre-capillary vascular bed around alveolar sacs but were not present one hour post-injection although Sertoli cell label and cellular debris was. Most of the injected nanoparticle load (70%) and curcumin load (80%) was present in the lungs 15 minutes post-injection, and remained at 70% and 80%, respectively, one hour post-injection.Type: GrantFiled: October 9, 2015Date of Patent: April 30, 2019Assignee: UNIVERSITY OF SOUTH FLORIDAInventors: Arun Kumar, Shyam S. Mohapatra, Don F. Cameron
-
Patent number: 10272054Abstract: Aqueous, topical antifungal compositions contain an allylamine or an azole as the antifungal agent together with a lactate ester, an organic acid (pKa 3.8-5), a C2 to C6 saturated aliphatic alcohol, and a cationic galactomannan gum.Type: GrantFiled: October 7, 2016Date of Patent: April 30, 2019Assignee: Exodos Life Sciences LPInventors: Servet Buyuktimkin, Nadir Buyuktimkin, James L. Yeager
-
Patent number: 10272055Abstract: Biguanide compounds and salts thereof are disclosed. Also disclosed are pharmaceutical compositions and therapeutic methods for treating certain diseases including cancer such as breast cancer.Type: GrantFiled: March 6, 2015Date of Patent: April 30, 2019Assignees: Regents of the University of Minnesota, The Regents of the University of CaliforniaInventors: David A. Potter, Zhijun Guo, Elizabeth Amin, Gunda Georg, Tom Poulos, Irina Sevrioukova
-
Patent number: 10272056Abstract: The present application relates to methods of treating a subject with a disease or disorder associated with a mitochondrial deficit, comprising: determining at least one of a type or degree of the mitochondrial deficit in the subject; and administering an amount of a butyrate compound to the subject based at least partially on the determining step so as to promote Adenosine triphosphate (ATP) production in the subject as well as to methods of screening for compounds that restore cellular mitochondrial activity.Type: GrantFiled: April 1, 2016Date of Patent: April 30, 2019Assignee: The George Washington University, A Congressionally Chartered Not-for-Profit CorporationInventors: Anne Chiaramello, Martine Uittenbogaard
-
Patent number: 10272057Abstract: The invention relates to layered double hydroxide (LDH) materials and in particular to new methods of preparing improved LDH materials which have intercalated active anionic compounds (improved LDH-active anion materials). The improved LDH-active anion materials are characterized by their high degree of robustness, demonstrated by their high Particle Robustness Factor values, and by their ability to retain substantially all of the intercalated active anionic compound, in the absence of ion exchange conditions and/or at pH>4.Type: GrantFiled: April 3, 2017Date of Patent: April 30, 2019Assignee: OXFORD PHARMASCIENCE LIMITEDInventors: Claire Thompson, Marcelo Leonardo Bravo Cordero, Dermot Michael O'Hare
-
Patent number: 10272058Abstract: Treatment of intrahepatic cholestatic diseases by therapy with seladelpar or a salt thereof.Type: GrantFiled: April 25, 2017Date of Patent: April 30, 2019Assignee: CymaBay Therapeutics, Inc.Inventors: Pol Boudes, Charles A. McWherter
-
Patent number: 10272059Abstract: The present invention relates to compositions containing, as active ingredient, a mixture of amino acids able to stimulate the biosynthesis of elastin and collagen.Type: GrantFiled: December 3, 2015Date of Patent: April 30, 2019Assignee: Professional Dietetics S.P.A.Inventor: Paolo Giorgetti
-
Patent number: 10272060Abstract: The invention is directed to microbial oils containing omega-3 polyunsaturated fatty acids comprising docosahexaenoic acid, eicosapentaenoic acid, and optionally docosapentaenoic acid and dosage forms containing such oils.Type: GrantFiled: February 6, 2018Date of Patent: April 30, 2019Assignee: DSM IP Assets B.V.Inventors: Kirk E. Apt, Paul Warren Behrens, Jon Milton Hansen, Joseph W. Pfeifer, III, Tracey Lynn Stahl, Ross Zirkle
-
Patent number: 10272061Abstract: The present invention provides compositions and methods for administering oxybutynin while minimizing the incidence and/or severity of adverse drug experiences associated with oxybutynin therapy. In one aspect, these compositions and methods provide a lower plasma concentration of oxybutynin metabolites, such as N-desethyloxybutynin, which is presumed to be contributing at least in part to some of the adverse drug experiences, while maintaining sufficient oxybutynin plasma concentration to benefit a subject with oxybutynin therapy. The invention also provides isomers of oxybutynin and its metabolites that meet these characteristics of minimized incidence and/or severity of adverse drug experiences, and maintenance of beneficial and effective therapy for overactive bladder. In some aspects, the composition may be presented in the form of an unoccluded or free form topically administered gel.Type: GrantFiled: November 10, 2016Date of Patent: April 30, 2019Assignee: ALLERGAN SALES, LLCInventors: Charles D. Ebert, Steven W. Sanders
-
Patent number: 10272062Abstract: Modified release formulations of gamma-hydroxybutyrate having improved dissolution and pharmacokinetic properties are provided, and therapeutic uses thereof.Type: GrantFiled: July 21, 2017Date of Patent: April 30, 2019Assignee: Flamel Ireland LimitedInventors: Claire Mégret, Hervé Guillard, Jean-François Dubuisson
-
Patent number: 10272063Abstract: Granulocyte colony-stimulating factor (G-CSF; a stem cell enhancer and facilitator), DETC-MeSO (a glutamate receptor partial antagonist and anti-excitotoxicity agent), and sulindac (a potent anti-oxidant and anti-inflammatory agent) each can protect brain tissue exposed to a cerebral ischemia/reperfusion injury, and minimize the size of infarcts that develop as a result of the injury. When administered in combination, these agents are effective at protecting brain tissue and minimizing the size of an infarct resulting from the injury at much lower concentrations compared to using a single agent.Type: GrantFiled: November 3, 2017Date of Patent: April 30, 2019Assignee: CHS Pharma, Inc.Inventors: Jang-Yen Wu, Howard Malcolm Prentice